Ocugen (OCGN) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Ocugen Provides Business Update & Second Quarter 2022 Financial Results
August 5, 2022 7:30 AM EDTDosing patients in U.S. Phase 2/3 COVAXIN (BBV152) clinical trialCompleted dosing of patients in Cohort 1 of OCU400 gene therapy product candidateExpanding product pipeline with the regenerative medicine cell therapy program NeoCart®
MALVERN, Pa., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:... More
